Geron Faces Investor Suit After FDA Halts Clinical Trial

Law360, New York (March 19, 2014, 7:03 PM EDT) -- Geron Corp. was hit with a shareholder class action Friday in California federal court accusing the drugmaker of improperly touting the prospects of its sole drug candidate before the U.S. Food and Drug Administration put a hold on the drug's clinical trial over concerns of liver toxicity.

Shares in Geron tanked more than 61 percent March 12 on news the company had received verbal communication from the FDA saying the agency was putting the trial of imetelstat, a drug that treats cancer, on hold.

The class action claims...
To view the full article, register now.

Related

Sections

Case Information

Case Title

In re: GERON CORPORATION SECURITIES LITIGATION


Case Number

3:14-cv-01224

Court

California Northern

Nature of Suit

Securities/Commodities

Judge

Charles R. Breyer

Date Filed

March 14, 2014

Law Firms

Government Agencies

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.